Literature DB >> 30554431

CXCR4 enhances cisplatin resistance of human tongue squamous cell carcinoma.

Xiu-Mei Zhuang1,2, Bin Zhou1,2.   

Abstract

BACKGROUND: The chemokine receptor 4 (CXCR4) plays an important role in tumor progression. Overexpressed CXCR4 is associated with a poor prognosis of patient with head and neck squamous cell carcinomas. However, the correlation between CXCR4 and chemotherapy resistance in tongue squamous cell carcinoma (TSCC) remains obscure.
METHODS: Stable cisplatin-resistant CAL27 CDDP and SCC25 CDDP cells were established and identified by CCK8 assay, and the CXCR4 expression was detected using qRT-PCR and Western blot. CXCR4-siRNA was transfected into TSCC CDDP cells, whose transfect efficiency was examined. Cisplatin sensitivity was further detected, as well as several proliferation and apoptosis-related proteins.
RESULTS: CAL27 CDDP and SCC25 CDDP cells were successfully established, which exhibited significantly higher cell viability and less apoptosis under cisplatin stimulation than that of parental cells. CXCR4 expression was increased in TSCC CDDP cells. After transfection of CXCR4-siRNA, the expression of CXCR4 was reduced by 73% and 78% in CAL27 CDDP and SCC25 CDDP cells, respectively. CCK8 assay and flow cytometry assay revealed that the proliferative capacity under cisplatin stimulation significantly decreased after CXCR4 silencing. Moreover, increased TSCC CDDP cells were arrested in the G0/G1 phase after knockdown of CXCR4. Compared with negative control group, the expression of cyclin D1 and p-AKT decreased, while that of p-caspase-3 and Bax significantly increased.
CONCLUSIONS: Silencing CXCR4 may evidently inhibit proliferation, induce apoptosis and enhance cisplatin sensitivity of TSCC CDDP cells by reduced cyclin D1 and p-AKT, and increased p-caspase-3 and Bax.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CXCR4; chemotherapy resistance; proliferation and apoptosis; tongue squamous cell carcinoma

Mesh:

Substances:

Year:  2018        PMID: 30554431     DOI: 10.1111/jop.12813

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  5 in total

1.  MK2206 Enhances Cisplatin-Induced Cytotoxicity and Apoptosis in Testicular Cancer Through Akt Signaling Pathway Inhibition.

Authors:  Dingqi Sun; Jinhua Wang; Hui Zhang; Shuai Liu; Peng Wei; Haoran Wang; Zhen Xu; Qiang Fu; Keqin Zhang
Journal:  Transl Oncol       Date:  2020-05-15       Impact factor: 4.243

2.  Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma.

Authors:  Ravindran Caspa Gokulan; Halagowder Devaraj
Journal:  Cancers (Basel)       Date:  2021-11-23       Impact factor: 6.639

3.  The upregulation of stromal antigen 3 expression suppresses the phenotypic hallmarks of hepatocellular carcinoma through the Smad3-CDK4/CDK6-cyclin D1 and CXCR4/RhoA pathways.

Authors:  Menglin Zhao; Yanyan Wang; Yue Zhang; Xinwei Li; Jiaqi Mi; Qiang Wang; Zhijun Geng; Lugen Zuo; Xue Song; Sitang Ge; Zining Zhang; Mingyue Tang; Huiyuan Li; Zishu Wang; Chenchen Jiang; Fang Su
Journal:  BMC Gastroenterol       Date:  2022-08-08       Impact factor: 2.847

4.  TUG1/miR-133b/CXCR4 axis regulates cisplatin resistance in human tongue squamous cell carcinoma.

Authors:  Ke Zhang; Hong Zhou; Bo Yan; Xuanping Cao
Journal:  Cancer Cell Int       Date:  2020-05-06       Impact factor: 5.722

5.  Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).

Authors:  Wenguang Wang; Zhilu Gan; Qiang Liu; Shenshen Yan; Rexiti Mulati; Yujie Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.